Skinvisible (SKVI) EBIT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 7.73% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -15.60% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 53.28% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 1.82% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 0.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.52% |
| Dec 31, 2025 | 1.01% |
| Sep 30, 2025 | 5.87% |
| Jun 30, 2025 | -53.04% |
| Mar 31, 2025 | -20.70% |
| Dec 31, 2024 | -49.58% |
| Sep 30, 2024 | -151.53% |
| Jun 30, 2024 | -42.51% |
| Mar 31, 2024 | -3.49% |
| Dec 31, 2023 | -170.11% |
| Sep 30, 2023 | 1.57% |
| Jun 30, 2023 | -106.77% |
| Mar 31, 2023 | 0.54% |
| Dec 31, 2022 | -0.07% |
| Sep 30, 2022 | 2.43% |
| Jun 30, 2022 | 37.81% |
| Mar 31, 2022 | 18.34% |
| Dec 31, 2021 | 43.61% |
| Sep 30, 2021 | 61.60% |